Navarro NM, Robles ZRE, Garibay EA, Ruiz BE, Escobar LR, Velázquez CCA

Language: Spanish
References: 20
Page: 66-70
PDF size: 146.44 Kb.

ABSTRACT

background. Several studies have shown a high prevalence of multidrug resistance to antibiotics in community-acquired uropathogenic Escherichia coli. The prevalence of resistant isolates is variable in different regions and it is important to conduct surveillance studies to select empirical treatment.
material and method. We studied 767 isolates of community-acquired uropathogenic Escherichia coli from Dr. Ignacio Chavez Medical Center (ICMC), San Jose Hospital (SJH), and Children’s Hospital of Sonora (CHS) of the City of Hermosillo, over a one year period (2008-2009). Identification tests and antibiotics susceptibility assays were performed using Vitek2 and MicroScan systems. The detection of extended-spectrum β-lactamases (ESBL) production was determined by means of double disk synergy with and without clavulanate.
results. The highest antibiotic resistance rates were observed to sulfamethoxazole-trimethoprim, aminopenicillin-inhibitor, and cefazolin, with accumulated 54.4%, 37.0%, and 21.5%, respectively. In contrast, the lowest resistance rates were observed against nitrofurantoin (0.0-11.3%), and cefoxitin (9.9%). Around 15% of the isolates were ESBL producers.
conclusions. There was a high antibiotic resistance rate to sulfamethoxazole-trimethoprim, aminopenicillin-inhibitor, and cefazolin in the isolates of community-acquired uropathogenic E. coli tested. In the bacteria isolates from HSJH and ICMC there was a high prevalence of fluoroquinolone resistance. The results obtained from this study are cause for epidemiological concern, and require a strict follow-up in the coming years.

REFERENCES

1. Sümer Z, Coskunkan F, Vahaboglu H, Bakir M. “The resistance of Escherichia coli strains isolated from community-acquired urinary tract infections”. Adv Therapy 2005; 22: 419-423.

2. Alós JI, Serrano MG, Gómez-Garcés JL, Perianes J. “Antibiotic resistance of Escherichia coli from community- acquired urinary tract infections in relation to demographic and clinical data”. Clin Microbiol Infect 2005; 11: 199-203.

3. Gobernado M, Valdés L, Alós JI, García Rey C, Dal Ré R, García de Lomas J. “Antimicrobial susceptibility of clinical Escherichia coli isolates from uncomplicated cystitis in women over a 1-year period in Spain”. Rev Esp Quimioter 2007; 20: 68-76.

4. Guajardo Lara CE, González Martínez PM, Ayala Gaytán JJ. “Resistencia antimicrobiana en la infección urinaria por Escherichia coli adquirida en la comunidad. ¿Cuál antibiótico voy a usar?” Sal Púb Méx 2009; 51: 157-161.

5. Santo E, Salvador MM, Marín JM. “Multidrug-resistant urinary tract isolates of Escherichia coli from Ribeirão Preto, São Paulo, Brazil”. Brazilian J Infect Diseases 2007; 11: 575-578.

6. Cornejo Juárez P, Velásquez -Acosta C, Sandoval S, Gordillo P, Volkow Fernández P. “Patrones de resistencia bacteriana en urocultivos en un hospital oncológico”. Sal Púb Méx 2007; 49: 330-336.

7. Gaspari RJ, Dickson E, Karlowsky J, Doern G. “Multidrug resistance in pediatric urinary tract infections”. Microbial Drug Resistance 2006; 12: 126-129.

8. Lerma M, Cebrián L, Giménez MJ, Coronel P, Gimeno M, Aguilar L, García de Lomas J. “β-lactam susceptibility of Escherichia coli isolates from urinary tract infections exhibiting different resistance phenotypes”. Rev Esp Quimioter 2008; 21: 149-152.

9. Zorc J, Kiddoo DA, Shaw KN. “Diagnosis and management of pediatric urinary tract infection”. Clin Microbiol Rev 2005; 18: 417-422.

10. CLSI. 2008. Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. Clinical and Laboratory Standards Institute. M100-S18. Wayne, PA.

11. Gupta K, Hooton TM, Naber KG, et al. “International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases”. Clin Inf Dis 2011; 52: e103-e120.

12. Farshad S, Ranjbar R, Anvarinejad M, Shahidi MA, Hosseini M. “Emergence of multi drug resistant strains of Escherichia coli isolated from urinary tract infection”. Open Conference Proceeding Journal 2010; 1: 192-196.

13. White B. “Diagnosis and treatment of urinary tract infections in children”. Am Fam Physician 2011; 83: 409-415.

14. Manikandan S, Ganesapandian S, Singh M, Kumaraguru AK. “Emerging of multidrug resistance human pathogens from urinary tract infections”. Curr Res Bacteriol 2011; 4: 9-15.

15. Horcajada JP, Fariñas MC. “Implicaciones de las resistencias bacterianas en las infecciones urinarias adquiridas en la comunidad”. Enferm Infecc Microbiol Clin 2005; 23: 1-3.

16. Aguirre Alvarado H, Plascencia Hernández A, Rivera Mendoza CC, Guerrero Becerra M. “Resistencia de Escherichia coli en infecciones de vías urinarias en pacientes pediátricos del Hospital Civil de Guadalajara “Fray Antonio Alcalde””. Enf Inf Microbiol 2007; 27: 83-87.

17. Alghasham AA, Nahata MC. “Clinical use of fluoroquinolones in children”. Ann Pharmacother 2000; 34: 247-259.

18. Tena D, González-Praetorius A, González JC, Heredero E, Illescas S, Sáinz de Baranda C, Seseña G. “Evolución del patrón de sensibilidad de Escherichia coli en infecciones del tracto urinario diagnosticadas en la comunidad durante el periodo 2003-2007. Estudio multicéntrico en Castilla la Mancha”. Rev Esp Quimioter 2010; 23: 36-42.

19. Coque TM, Baquero F, Canton R. “Increasing prevalence of ESBL producing enterobacteriaceae in Europe”. Eurosurveillance 2008; 13: 1-11.

20. Karlowsky JA, Hoban DJ, DeCorby MR, Laing NM, Zhanel GG. “Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: Results from the North American urinary tract infection collaborative alliance-quinolone resistance study”. Antimicrobial Agents Chemother 2006; 50: 2254-2254.